Onasemnogene abeparvovec, sold under the brand name Zolgensma, is a gene therapy medication used to treat spinal muscular atrophy (SMA). It was approved for children less than two years old in 2019. It is used as a one-time injection into a vein with at least two months of corticosteroids. Onasemnogene abeparvovec was approved for medical use in the United States in 2019, and in Japan and the European Union in 2020.<\/p>\n
Note:<\/strong> ZOLGENSMA (Onasemnogene abeparvovec-xioi) for injection is used for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA).<\/p>\n If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import Onasemnogene abeparvovec-xioi for injection\u201d<\/strong> based on the information you provide.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n","protected":false},"excerpt":{"rendered":"onasemnogene abeparvovec-xioi Suspension for intravenous infusion Initial U.S. Approval: 2019<\/h2>\n
Access the best support services globally<\/h4>\n